Takeda Pharmaceutical Co Ltd ADR (TAK)vsTherapeuticsMD Inc (TXMD)
TAK
Takeda Pharmaceutical Co Ltd ADR
$18.29
+1.39%
HEALTHCARE · Cap: $56.99B
TXMD
TherapeuticsMD Inc
$2.29
0.00%
HEALTHCARE · Cap: $26.51M
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 159677230% more annual revenue ($4.46T vs $2.80M). TXMD leads profitability with a 10.8% profit margin vs 2.5%. TAK trades at a lower P/E of 82.0x. TAK earns a higher WallStSmart Score of 60/100 (C).
TAK
Buy60
out of 100
Grade: C
TXMD
Hold39
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-77.5%
Fair Value
$10.30
Current Price
$18.29
$7.99 premium
Margin of Safety
-3357.1%
Fair Value
$0.07
Current Price
$2.29
$2.22 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Reasonable price relative to book value
Generating 317.5B in free cash flow
Large-cap with strong market position
Reasonable price relative to book value
Revenue surging 43.3% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
4.2% revenue growth
3.3% earnings growth
ROE of 1.5% — below average capital efficiency
2.5% margin — thin
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.3% — below average capital efficiency
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, Free Cash Flow. PEG of 0.39 suggests the stock is reasonably priced for its growth.
Bull Case : TXMD
The strongest argument for TXMD centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 43.3% demonstrates continued momentum.
Bear Case : TAK
The primary concerns for TAK are Revenue Growth, EPS Growth, Return on Equity. A P/E of 82.0x leaves little room for execution misses. Thin 2.5% margins leave little buffer for downturns.
Bear Case : TXMD
The primary concerns for TXMD are EPS Growth, Market Cap, Return on Equity. A P/E of 229.0x leaves little room for execution misses.
Key Dynamics to Monitor
TAK profiles as a value stock while TXMD is a growth play — different risk/reward profiles.
TXMD carries more volatility with a beta of 0.54 — expect wider price swings.
TXMD is growing revenue faster at 43.3% — sustainability is the question.
TAK generates stronger free cash flow (317.5B), providing more financial flexibility.
Bottom Line
TAK scores higher overall (60/100 vs 39/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
TherapeuticsMD Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
TherapeuticsMD, Inc. is a women's healthcare company in the United States. The company is headquartered in Boca Raton, Florida.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?